Keywords
Child
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To report the majority of drugs used to treat Osteogenesis Imperfecta (OI) in children. Methods: The methodological part of this integrative review is formed by the National Library of Medicine, the Virtual Health Library and the Cochrane library, which were the databases used to form the bibliographic compilation of this literature review. The descriptors used were “Osteogenesis Imperfecta”, “children” and “treatment”. Inclusion criteria were articles from clinical trials, randomized or non-randomized, case-control studies, cohort studies, free access, published in English, Portuguese, Spanish and in the period from 2012 to 2022. Results: A total of nine articles for an evaluation of which drug would be more effective, the drugs tested were these: Vitamin D, Risedronate, Bisphosphonates, Zoledronic acid (ZOL), oral Alendronate (ALN), Denosumab, Physical Exercises, Mesenchymal stem cells (MSCs), Neridronate and Fresolimumab (Anti TGF-β). The nine selected articles were evaluated and from this process an explanatory framework was developed consisting of author, year of publication, sample, medications and results. Final considerations: The analysis of the entire context makes us reflect, through the bibliographic sources, that there is a need for new publications, since society knows little information on the subject.
References
BISHOP N, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. The Lancet, 2013; 382(9902): 1424–32.
BORGES CC e OLIVEIRA MNR. Problemas Internalizantes e Externalizantes de Crianças e Adolescentes com Fibrose Cística. Psicol cienc prof, 2022; 42: 233513.
BOTOR M, et al. Osteogenesis Imperfecta: Current and Prospective Therapies. Biomolecules, 2021; 11(10): 1493.
BRIZOLA E, et al. Características clínicas e padrão de fraturas no momento do diagnóstico de osteogênese imperfeita em crianças. Rev paul pediatr, 2017; 35(2): 171–177.
CAMPANA MB, et al. Exercício na osteogênese imperfeita. Acta Fisiátrica, 2014; 21(2): 80–86.
D'EUFEMIA P, et al. Serum creatine kinase isoenzymes in children with osteogenesis imperfecta. Osteoporos Int, 2017; 28(1): 339-346.
HÖGLER W, et al. The Effect of Whole-Body Vibration Training on Bone and Muscle Function in Children with Osteogenesis Imperfecta. The Journal of Clinical Endocrinology & Metabolism, 2017; 102(8): 2734–43.
HOYER-KUHN H, et al. Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial. Journal of Musculoskeletal & Neuronal Interactions, 2016; 16(1): 24–32.
IDOLAZZI L, et al. Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study. Bone, 2017; 103: 144-149.
INFANTE A, et al. Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro‐osteogenic paracrine response: TERCELOI clinical trial. Clinical and Translational Medicine, 2021; 11(1).
LV F, et al. Ácido zoledrônico versus alendronato no tratamento de crianças com osteogênese imperfeita: um estudo clínico de 2 anos. Endocr Pract, 2018; 24(2): 179–188.
MARTINS G, et al. Sintomas urinários e intestinais experimentados por crianças com osteogênese imperfeita. Jornal de Pediatria, 2020; 96(4): 472–478.
MENDES BV, et al. Intervenções não farmacológicas em procedimentos dolorosos com agulhas em crianças: revisão integrativa. Brazilian Journal Of Pain, 2022; 5(1).
NIJHUIS W, et al. A standard set of outcome measures for the comprehensive assessment of osteogenesis imperfecta. Orphanet Journal of Rare Diseases, 2021; 16(1).
PILEGGI VN, et al. Ângulo de fase e critérios da Organização Mundial da Saúde para avaliação do estado nutricional em crianças com osteogênese imperfeita. Revista Paulista de Pediatria, 2016; 34(4): 484–488.
PLANTE L, et al. Efeito da suplementação de vitamina D em altas doses na densidade óssea em jovens com osteogênese imperfeita: um estudo controlado randomizado. Osso, 2016; 86: 36–42.
SONG IW, et al. Targeting TGF-β for treatment of osteogenesis imperfecta. The Journal of Clinical Investigation, 2022; 132(7).
VALLE CAR, et al. Influência da hipovitaminose D na ocorrência das fraturas. Rev Bras Ortop, 2021; 56(06): 784–789.
VARENNA M, et al. Tratamento da síndrome de dor regional complexa tipo I com neridronato: um estudo randomizado, duplo-cego, controlado por placebo. Rheumatology, 2013; 52(3): 534–542.
VEILLEUX LN, et al. Anatomia muscular e função muscular dinâmica na osteogênese imperfeita tipo I. J Clin Endocrinol Metab, 2014; 99(2): 356-362.